Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
Rachel ThijssenSilvia Alvarez-DiazClea GraceMing-Yuan GaoDavid H SegalZhen XuAndreas StrasserDavid Ching Siang HuangPublished in: Cell death and differentiation (2020)